Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
62.35%
Operating Margin
39.53%
Net Margin
29.15%
Efficiency Metrics
Revenue per Expense Ratio
1.65
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
71.25%
Income Tax Rate
22.81%
EPS
2.6100000000
Balance Sheet Analysis
Current Ratio
0.77
Cash Ratio
0.37
Working Capital
$-1.32B
Debt to Equity
2.13
Debt to Assets
50.28%
Equity Ratio
23.57%
Cash Flow Analysis
Operating Cash Flow Ratio
55.51%
Free Cash Flow Ratio
30.91%
CapEx to Revenue
24.61%
Dividends Paid
$2.18B
Stock Buybacks
$130.00M
Total Shareholder Returns
$2.31B
Cash Position Change
1,314.5%
Key Takeaways (2023 FY)
Revenue declined by 0.52895576835385%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 5.26%
Detailed Growth Metrics
Core Performance
Revenue
-0.53%
Net Income
55.15%
EPS
55.36%
Operating Income
42.84%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
4.56%
Operating Cash Flow
21.46%
Free Cash Flow
29.36%
Balance Sheet Health
Assets
8.66%
Debt
15.53%
Book Value per Share
6.07%
Inventory
-14.38%
Shareholder Returns
Dividends per Share
5.26%
Shares Outstanding
-0.05%
Long Term Trends
3Y Revenue/Share
40.82%
5Y Revenue/Share
0.39%
3Y Dividend/Share
11.88%
5Y Dividend/Share
25.69%